HDAC9 and B-cell non-Hodgkin lymphoma: In fact, inhibition of HDACs has been reported to have promising effects in cancer treatment.18 However, most HDIs are disadvantaged by their lack of enzyme specificity and have a broad range of potential side effects.28 Our findings from this study reveal an unexpected anti-oncogenic function for an HDAC in pro-B-ALL and B-cell lymphoma.